<article>
<section>
<h1 id="header">An optimized protocol for the retroviral transduction of mouse CD4 T cells</h1>
<p><time datetime="2021-08-06">Published: August 6, 2021</time></p>
<p>Ekaterina Eremenko,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff3">3</a>,<a href="#aff4">4</a>,<a href="#fn1">5</a>,<a href="#fn2">6</a>,<a href="#fn3">7</a>,<a href="#cor1">*</a></sup> Zoe V. Taylor,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff4">4</a>,<a href="#fn1">5</a></sup> Bishnu Khand,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff4">4</a></sup> Shir Zaccai,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff3">3</a>,<a href="#aff4">4</a></sup> Angel Porgador,<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff4">4</a>,<a href="#cor3">***</a></sup> and Alon Monsonego<sup><a href="#aff1">1</a>,<a href="#aff2">2</a>,<a href="#aff4">4</a>,<a href="#cor2">**</a></sup></p>
<p id="aff1"><sup>1</sup>The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel</p>
<p id="aff2"><sup>2</sup>The Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel</p>
<p id="aff3"><sup>3</sup>The Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel</p>
<p id="aff4"><sup>4</sup>The National Institute of Biotechnology in the Negev, Zlotowski Neuroscience Center, and Regenerative Medicine and Stem Cell Research Center, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel</p>
<p id="fn1"><sup>5</sup>These authors contributed equally</p>
<p id="fn2"><sup>6</sup>Technical contact</p>
<p id="fn3"><sup>7</sup>Lead contact</p>
<p id="cor1"><sup>*</sup>Correspondence: <a href="mailto:eremenkoem@gmail.com">eremenkoem@gmail.com</a></p>
<p id="cor2"><sup>**</sup>Correspondence: <a href="mailto:alonmon@bgu.ac.il">alonmon@bgu.ac.il</a></p>
<p id="cor3"><sup>***</sup>Correspondence: <a href="mailto:angel@bgu.ac.il">angel@bgu.ac.il</a></p>
<p><span class="open-access">Open Access</span> • DOI: <a href="https://doi.org/10.1016/j.xpro.2021.100719">10.1016/j.xpro.2021.100719</a></p>
</section>
<section>
<h2 id="summary">Summary</h2>
<p>Transduction of primary T cells has become prominent with the introduction of chimeric antigen receptor T-cell therapy. Although there are many protocols for the transduction of human T cells, it remains a challenge to transduce murine T cells. We present an optimized protocol for the retroviral transduction of murine CD4 T cells, which overcomes major challenges including large-scale production and long-term culturing of transduced cells. The optimized protocol combines high transduction efficiency with a low rate of cell death.</p>
<p>For complete details on the use and execution of this protocol, please refer to <a href="#bib6">Eremenko et al., 2019</a>.</p>




<div class="highlights">
<h3>Highlights</h3>
<ul>
<li>Detailed description of retroviral transduction of murine CD4 T cells</li>
<li>Large-scale production of murine CD4-transduced T cells</li>
<li>Enhanced proliferation and viability of murine CD4-transduced T cells with IL-2/IL-7</li>
</ul>
</div>
<div class="graphical-abstract">
<h3>Graphical abstract</h3>
<figure><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/906-GA.jpg" alt="GraphicalAbstract.jpg"></figure>
</div></section>
<section>
<h2 id="before-you-begin">Before you begin</h2>
<p>This protocol describes an efficient method for the transduction of CD4 murine T cells, based on retroviral (RV) delivery of genes of interest. It presents as a useful resource for the generation of mouse CAR-T cells, enabling researchers to drive this area of research forward.</p>
<p>The common protocol includes several steps such as, viral packaging, isolation and preparation of CD4 T cells for viral transduction and expansion of the transduced cells in culture. This optimized protocol enables the large-scale production of RV-transduced T cells, previously presented as a major challenge, owing to the limited proliferation capability and poor cell survival. Our protocol utilizes the packaging cell line, Platinum-E (Plat-E) cells, to produce retroviral particles, which can stably produce retroviruses with an average titer of 1 × 10<sup>7</sup> cfu/mL (<a href="#bib10">Morita et al., 2000</a>).</p>
<p>Although it is widely accepted that IL-2 is necessary for T cell cultures (<a href="#bib14">Zhang et al., 2020</a>), recent studies indicate the benefit of adding other cytokines, such as IL-7 and IL-15 (<a href="#bib13">Xu et al., 2014</a>; <a href="#bib2">Alvarez-Fernández et al., 2016</a>; <a href="#bib7">Hurton et al., 2016</a>; <a href="#bib1">Alizadeh et al., 2019</a>).</p>
<p>IL-7, was found to maintain the survival of human T cells in vitro (<a href="#bib11">Rathmell et al., 2001</a>). We found that the combination of IL-2 and IL-7 increased the long-term survival of mouse CD4-transduced T cells.</p>
<p>When working with RV supernatants and RV-transduced samples it is important to follow the universal precautions. All experiments should be carried out in at least a class II biological safety cabinet with appropriate protective equipment, including a lab coat, protective sleeves, and double gloves. Detergents or ethanol can readily inactivate retroviruses owing to the retrovirus being surrounded by a lipid membrane derived from the virus-producing cell (<a href="#bib3">Coffin et al., 1997</a>).</p>
<h3 id="sec1.1">Culturing plat-E cells</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2 weeks</div>
<ol>
<li>Thaw Plat-E cells, routinely stored at −80°C.</li>
<li>Suspend in 15 mL 293T medium and incubate in a 75 cm<sup>2</sup> flask at 37°C in a humidified 5% CO<sub>2</sub>-containing incubator.</li>
<li>Once the cells reach a confluence of around 85%–90%, detach cells by adding 2 mL trypsin-EDTA 0.05% and incubate at 37°C in a humidified 5% CO<sub>2</sub>-containing incubator for 3 min.</li>
<li>Collect the cells into a 15 mL conical tube followed by washing the flask with 8 mL 293T medium.</li>
<li>Centrifuge at 500 × <i>g</i> for 5 min at 22°C.</li>
<li>Remove the supernatant and resuspend the cells in Plat-E medium. Divide the cells to two new 75 cm<sup>2</sup> flasks and make up to 15 mL with Plat-E medium.</li>
<li>Incubate at 37°C in a humidified 5% CO<sub>2</sub>-containing incubator.</li>
<li>Treat cells biweekly, as described above.</li>
</ol>
<h3 id="sec1.2">Mice</h3>
<ol start="9">
<li>Ideally use male or female, 8–12 weeks old C57BL/6 mice.</li>
</ol>
<p><b>Note:</b> Mice are housed under standard conditions, in a 12-h light/dark cycle with food and water supplied <i>ad libitum</i>. All procedures are performed under the approval of the Ben-Gurion University of the Negev Animal Care and Use Committee. All efforts are made to minimize suffering of the animals.</p>
<h3 id="sec1.3">Plasmid generation</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 2 h</div>
<ol start="10">
<li>Prepare plasmid stocks using standard molecular biology techniques following the manufacturer instructions of the Purelink<sup>TM</sup> HiPure Plasmid Filter Maxiprep Kit (Invitrogen) or an alternative preferred kit.</li>
<li>Determine the DNA concentration of the plasmid using NanoDrop spectrophotometer.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Ensure there is sufficient plasmid concentration for the experiment.</div>
</section>
<section>
<h2 id="key-resources-table">Key resources table</h2>
<table id="krt">
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Chemicals, peptides, and recombinant proteins</td>
</tr>
<tr>
<td>Poly-D-lysine</td>
<td>Sigma-Aldrich</td>
<td>P6407</td>
</tr>
<tr>
<td>PureLink<sup>TM</sup> HiPure Plasmid Filter Maxiprep Kit</td>
<td>Invitrogen</td>
<td>K210016</td>
</tr>
<tr>
<td>Trypsin-EDTA 0.05 %, phenol red</td>
<td>Gibco</td>
<td>25300054</td>
</tr>
<tr>
<td>DMEM Medium</td>
<td>Gibco</td>
<td>11965092</td>
</tr>
<tr>
<td>Blasticidin (10 mg/mL) in HEPES Buffer</td>
<td>InvivoGen</td>
<td>Ant-bl-05</td>
</tr>
<tr>
<td>Puromycin (10 mg/mL) in H<sub>2</sub>O</td>
<td>Sigma-Aldrich</td>
<td>P9620</td>
</tr>
<tr>
<td>Penicillin-Streptomycin Solution (100×)</td>
<td>Biological Industries</td>
<td>03-031-1B</td>
</tr>
<tr>
<td>Isoflurane</td>
<td>Primal Critical Care</td>
<td>NDC66794-017</td>
</tr>
<tr>
<td>pMP71 Gpre GFP plasmid</td>
<td>Kindly provided by Professor Wolfgang Uckert, Max Delbrück Center for Molecular Medicine, Berlin, Germany</td>
<td>N/A</td>
</tr>
<tr>
<td>Lipofectamine™ Transfection Reagent</td>
<td>Invitrogen</td>
<td>18324012</td>
</tr>
<tr>
<td>ACK Lysing Buffer</td>
<td>Gibco</td>
<td>A1049201</td>
</tr>
<tr>
<td>Normal Rat Serum</td>
<td>STEMCELL Technologies</td>
<td>13551</td>
</tr>
<tr>
<td>EDTA 0.5 M, pH 8.0</td>
<td>Bio-Lab</td>
<td>009012230100</td>
</tr>
<tr>
<td>Water, Cell Culture Grade</td>
<td>Biological Industries</td>
<td>03-055-1A</td>
</tr>
<tr>
<td>Human IL-2</td>
<td>PeproTech</td>
<td>200-02-10UG</td>
</tr>
<tr>
<td>Mouse Recombinant IL-7</td>
<td>STEMCELL Technologies</td>
<td>78054</td>
</tr>
<tr>
<td>Fetal Bovine Serum</td>
<td>Gibco</td>
<td>10500-064</td>
</tr>
<tr>
<td>RPMI Medium 1640</td>
<td>Gibco</td>
<td>21875</td>
</tr>
<tr>
<td>HEPES Buffer Solution (1M)</td>
<td>Biological Industries</td>
<td>03-025-1B</td>
</tr>
<tr>
<td>MEM Non-Essential Amino Acids Solution (10 mM)</td>
<td>Biological Industries</td>
<td>01-340-1B</td>
</tr>
<tr>
<td>Sodium Pyruvate (100 mM)</td>
<td>Biological Industries</td>
<td>03-042-1B</td>
</tr>
<tr>
<td>β-Mercaptoethanol (14.3 M)</td>
<td>Sigma-Aldrich</td>
<td>M3148</td>
</tr>
<tr>
<td>Hank's Balanced Salt Solution (HBSS), no Phenol Red</td>
<td>Biological Industries</td>
<td>02-016-1A</td>
</tr>
<tr>
<td>Dulbecco's Phosphate Buffered Saline (PBS), without Calcium and Magnesium</td>
<td>Biological Industries</td>
<td>02-023-1A</td>
</tr>
<tr>
<td>Bovine Serum Albumin</td>
<td>MP Biomedicals</td>
<td>160069</td>
</tr>
<tr>
<td>Cell Trace Blue Cell Proliferation Kit</td>
<td>Invitrogen</td>
<td>C34568</td>
</tr>
<tr>
<td>eBioscience Fixable Viability Dye eFlour 780</td>
<td>Invitrogen</td>
<td>65-0865-14</td>
</tr>
<tr>
<td colspan="3">Experimental models: Cell lines</td>
</tr>
<tr>
<td>Plat-E Cells</td>
<td>Cell Biolabs</td>
<td>RV-101</td>
</tr>
<tr>
<td colspan="3">Experimental models: Organisms/strains</td>
</tr>
<tr>
<td>C57BL/6</td>
<td>Jackson</td>
<td>000664</td>
</tr>
<tr>
<td colspan="3">Other</td>
</tr>
<tr>
<td>Biological Safety Cabinet</td>
<td>NuAire</td>
<td>NU 425-600E</td>
</tr>
<tr>
<td>FACSAria<sup>TM</sup> III Cell Sorter</td>
<td>BD</td>
<td>648282</td>
</tr>
<tr>
<td>Centrifuge</td>
<td>Eppendorf</td>
<td>5810R</td>
</tr>
<tr>
<td>NanoDrop One Microvolume UV-Vis Spectrophotometer with Wi-Fi</td>
<td>Thermo Scientific™</td>
<td>ND-ONE-W</td>
</tr>
<tr>
<td>Counting Chamber</td>
<td>Paul Marienfeld GmbH &amp; Co.KG</td>
<td>0610010</td>
</tr>
<tr>
<td>15 mL Conical Tubes</td>
<td>Corning</td>
<td>188261</td>
</tr>
<tr>
<td>50 mL Conical Tubes</td>
<td>Corning</td>
<td>227270</td>
</tr>
<tr>
<td>10 cm Cell Culture Petri Dish Nunclon<sup>TM</sup> Delta Surface</td>
<td>Nunc<sup>TM</sup>
</td>
<td>150350</td>
</tr>
<tr>
<td>Non-Treated Multidishes 24 wells</td>
<td>Nunc<sup>TM</sup>
</td>
<td>144530</td>
</tr>
<tr>
<td>Cell-Culture Treated Multidishes 24 wells</td>
<td>Nunc<sup>TM</sup>
</td>
<td>142475</td>
</tr>
<tr>
<td>96 Well Round (U) Bottom Plate</td>
<td>Nunc<sup>TM</sup>
</td>
<td>163320</td>
</tr>
<tr>
<td>Serological Pipette 10 mL Sterile Individually Wrap</td>
<td>Bar-Naor</td>
<td>BNP10S1IPG</td>
</tr>
<tr>
<td>Serological Pipette 5 mL Sterile Individually Wrap</td>
<td>Bar-Naor</td>
<td>BNP5S1IPG</td>
</tr>
<tr>
<td>1.5 mL Eppendorf Tubes</td>
<td>Axygen</td>
<td>MCT-150-C</td>
</tr>
<tr>
<td>70 μm Cell Strainer</td>
<td>SPL</td>
<td>93070</td>
</tr>
<tr>
<td>3 mL Disposable Syringe without Needle</td>
<td>MediPlus</td>
<td>KL 3ML</td>
</tr>
<tr>
<td>DynaMag<sup>TM</sup>-2 Magnet</td>
<td>Invitrogen</td>
<td>12321D</td>
</tr>
<tr>
<td>EasySep<sup>TM</sup> Magnet</td>
<td>STEMCELL Technologies</td>
<td>18000</td>
</tr>
<tr>
<td>CytoFLEX LX Flow Cytometer</td>
<td>Beckman Coulter</td>
<td> </td>
</tr>
<tr>
<td>Dissecting Scissors</td>
<td>Kent Scientific</td>
<td>INS600393-G</td>
</tr>
<tr>
<td>Forceps</td>
<td>Kent Scientific</td>
<td>INS650914-4</td>
</tr>
</tbody>
</table>
<div class="alternatives">
<span class="alternatives-title">Alternatives:</span> In theory, all reagents and resources listed in the ‘key resources table’ can be substituted with equivalent items from other suppliers, with exception to the critical commercial assays and Nunc<sup>TM</sup> Non-Treated Multi-dishes 24 wells; however, it should be noted that the protocol has been calibrated to the reagents listed in the above table and alternatives have not been tested on the protocol performance.</div>
</section>
<section>
<h2 id="materials-and-equipment">Materials and equipment</h2>
<table id="undtbl1">
<caption>293T Medium</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount for 500 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal Bovine Serum</td>
<td>10% (v/v)</td>
<td>50 mL</td>
</tr>
<tr>
<td>Penicillin-Streptomycin Solution (100×)</td>
<td>1 mg/mL Streptomycin,100 U/mL Penicillin</td>
<td>5 mL</td>
</tr>
<tr>
<td>DMEM Medium</td>
<td>n/a</td>
<td>To 500 mL</td>
</tr>
</tbody>
</table>
<p class="table-legend">Store at 4°C for up to one month.</p>
<table id="undtbl2">
<caption>Plat-E Medium</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount for 500 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal Bovine Serum</td>
<td>10% (v/v)</td>
<td>50 mL</td>
</tr>
<tr>
<td>Penicillin-Streptomycin Solution (100×)</td>
<td>1 mg/mL Streptomycin,100 U/mL Penicillin</td>
<td>5 mL</td>
</tr>
<tr>
<td>Puromycin (10 mg/mL) in H<sub>2</sub>O</td>
<td>1 μg/mL</td>
<td>50 μL</td>
</tr>
<tr>
<td>Blasticidin (10 mg/mL) in HEPES buffer</td>
<td>10 μg/mL</td>
<td>500 μL</td>
</tr>
<tr>
<td>DMEM Medium</td>
<td>n/a</td>
<td>To 500 mL</td>
</tr>
</tbody>
</table>
<p class="table-legend">Store at 4°C for up to one month.</p>
<table id="undtbl3">
<caption>Complete RPMI Medium</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount for 500 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal Bovine Serum</td>
<td>10% (v/v)</td>
<td>50 mL</td>
</tr>
<tr>
<td>Penicillin-Streptomycin Solution (100×)</td>
<td>1 mg/mL Streptomycin,100 U/mL Penicillin</td>
<td>5 mL</td>
</tr>
<tr>
<td>HEPES Buffer Solution (1M)</td>
<td>10 mM</td>
<td>5 mL</td>
</tr>
<tr>
<td>MEM Non-Essential Amino Acids Solution (10 mM)</td>
<td>0.1 mM</td>
<td>5 mL</td>
</tr>
<tr>
<td>Sodium Pyruvate (100 mM)</td>
<td>1 mM</td>
<td>5 mL</td>
</tr>
<tr>
<td>β-mercaptoethanol (14.3 M)</td>
<td>50 μM</td>
<td>1.75 μL</td>
</tr>
<tr>
<td>RPMI Medium 1640</td>
<td>n/a</td>
<td>To 500 mL</td>
</tr>
</tbody>
</table>
<p class="table-legend">Store at 4°C for up to one month.</p>
<table id="undtbl4">
<caption>EasySep<sup>TM</sup> Mouse CD4 T-cell Isolation Kit Recommended Medium</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount for 100 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal Bovine Serum</td>
<td>2% (v/v)</td>
<td>2 mL</td>
</tr>
<tr>
<td>EDTA 0.5 M, pH 8.0</td>
<td>1 mM</td>
<td>200 μL</td>
</tr>
<tr>
<td>Dulbecco's Phosphate Buffered Saline (PBS), without Calcium and Magnesium</td>
<td>n/a</td>
<td>To 100 mL</td>
</tr>
</tbody>
</table>
<p class="table-legend">Aliquot and store at - 20°C for up to one year.</p>
<table id="undtbl5">
<caption>Dynabeads<sup>TM</sup> Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation Buffer</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount for 100 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bovine Serum Albumin</td>
<td>0.1% (w/v)</td>
<td>0.1 g</td>
</tr>
<tr>
<td>EDTA 0.5 M, pH 8.0</td>
<td>2 mM</td>
<td>400 μL</td>
</tr>
<tr>
<td>Dulbecco's Phosphate Buffered Saline (PBS), without Calcium and Magnesium</td>
<td>n/a</td>
<td>To 100 mL</td>
</tr>
</tbody>
</table>
<p class="table-legend">Aliquot and store at - 20°C for up to one year.</p>
<table id="undtbl6">
<caption>Cell Sorting Medium</caption>
<thead>
<tr>
<th>Reagent</th>
<th>Final concentration</th>
<th>Amount for 500 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal Bovine Serum</td>
<td>20% (v/v)</td>
<td>100 mL</td>
</tr>
<tr>
<td>Penicillin-Streptomycin Solution (100×)</td>
<td>2 mg/mL Streptomycin,200 U/mL Penicillin</td>
<td>10 mL</td>
</tr>
<tr>
<td>RPMI Medium 1640</td>
<td>n/a</td>
<td>To 500 mL</td>
</tr>
</tbody>
</table>
<p class="table-legend">Store at 4°C for up to one month.</p>
</section>
<section>
<h2 id="step-by-step-method-details">Step-by-step method details</h2>
<h3 id="sec3.1">Retroviral virus production</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 4 days</div>
<p>Plat-E cells were transfected with a DNA plasmid to produce the retroviral particles</p>
<p>Day 1: Plat - E seeding</p>
<ol>
<li>Before starting, ensure you have enough plasmid for transfection, step 8.</li>
<li>Coat 10 cm plates by adding 5 mL of 50 μg/mL poly-D-lysine in sterile water. Incubate at 22°C for 45 min. Wash twice with sterile water to ensure no residues remain.</li>
<li>Detach Plat-E cells, previously cultured in Plat-E medium in a 75 cm<sup>2</sup> flask. First, aspirate the culture medium and carefully add 2 mL pre-warmed trypsin-EDTA 0.05%. Incubate at 37°C in a humidified 5% CO<sub>2</sub>-containing incubator until the cells are detached, 3–5 min. Wash flask out with 8 mL medium and collect the supernatant in a 15 mL conical tube. Wash cells twice by centrifuging at <i>500</i> × <i>g</i> for 5 min and replacing the supernatant with fresh medium.</li>
<li>Count the cells using a hemocytometer.</li>
<li>Seed Plat-E cells in the coated plates, 3 × 10<sup>6</sup> cells per plate.</li>
<li>Incubate for 16 h at 37°C in a humidified 5% CO<sub>2</sub>-containing incubator.</li>
</ol>
<p>Day 2: Transfection of Plat-E cells</p>
<ol start="7">
<li>Once Plat-E cells are 85%–90% confluent, replace the medium with 10 mL DMEM medium supplemented with 10% (v/v) FBS and 1 mg/mL streptomycin, 100 U/mL penicillin.</li>
<li>Prepare the materials for transfection by adding the required volume of DMEM, without supplements, to each 1.5 mL Eppendorf tube. In one tube add 15 μg of the DNA plasmid [in this case pMP71Gpre GFP (<a href="#bib5">Engels et al., 2003</a>)] and in the other tube add 45 μL Lipofectamine.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> The final volume in each Eppendorf tube should be 250 μL.</div>
<div class="note">
<span class="note-title">Note:</span> The concentration of the plasmid is checked prior to transfection.</div>
<ol start="9">
<li>Transfer the diluted Lipofectamine to the diluted DNA solution and immediately pipette up and down 3–4 times.</li>
<li>Incubate at 22°C for 20 min to allow Lipofectamine/DNA complexes to form.</li>
<li>After 20 min, mix well and add (dropwise) to the Plat-E plates.</li>
<li>Gently swirl the plate and incubate for 16 h at 37°C in a humidified 5% CO<sub>2</sub> containing incubator.</li>
<li>Replace the medium with DMEM medium supplemented with 10% (v/v) FBS and 1 mg/mL streptomycin, 100 U/mL penicillin.</li>
</ol>
<h3 id="sec3.2">Isolation and activation of CD4 T cells</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 1 day</div>
<p>CD4 T cells were isolated from C57BL/6 mice spleens and subsequently activated with Dynabeads™ Mouse T-Activator CD3/CD28</p>
<p>Day 3: Isolation of CD4 T cells from mouse spleens and activation with Dynabeads™ Mouse T-Activator CD3/CD28</p>
<ol start="14">
<li>Check the fluorescence of the transfected Plat-E cells to determine transfection efficiency.</li>
<li>The day after transfection, sacrifice male or female C57BL/6 mice, aged 8–12 weeks, with an overdose of isoflurane and harvest the spleens. Collect the spleens to a 10 cm petri-dish filled with 5 mL HBSS.</li>
<li>In a BSC2 hood, wash the spleens in 5 mL HBSS in a 10 cm plate.</li>
<li>Transfer the washed spleens to a 70 μm cell strainer, placed within a 10 cm plate, with 4 mL HBSS, and using the ridged side of a 3 mL syringe plunger mash the spleens through the cell strainer (<a href="#fig1">Figure 1</a>). Rinse with 10 mL HBSS and transfer the cell suspension to a 15 mL conical tube.
<figure id="fig1"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/906-Fig1.jpg" alt="Fig1.jpg">
<figcaption>
<div class="figcaption-title">Figure 1. Schematic overview of the retroviral transduction protocol</div>
<p>Step 1: CD4 T cells are isolated from spleens of C57BL/6 mice; Step 2: The retroviral particles are produced using the Plat-E packaging cell line; and Step 3: The CD4 T cells are transduced with the retrovirus.</p>
</figcaption>
</figure>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> You will get approximately 80 × 10<sup>6</sup> leukocytes per spleen.</div>
<ol start="18">
<li>Centrifuge at <i>500</i> × <i>g</i> for 5 min at 4°C.</li>
<li>Remove the HBSS and add 300 μL ACK lysing buffer per spleen. Gently mix with the pellet and incubate for 1 min at 22°C. Next, add 10 mL HBSS and centrifuge at <i>500</i> × <i>g</i> for 5 min at 4°C. If the pellet remains red after centrifugation, remove the HBSS and add 150 μL ACK lysing buffer per spleen and incubate at 22°C for 45 s. Next, add 10 mL HBSS and centrifuge at <i>500</i> × <i>g</i> for 5 min at 4°C.</li>
<li>Remove the HBSS and wash twice by adding 10 mL HBSS and centrifuge at <i>500</i> × <i>g</i> for 5 min at 4°C.</li>
<li>Isolate CD4 T cells using the EasySep™ Mouse CD4 T Cell Isolation Kit as per manufacturer's instructions.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> You will get approximately 10% CD4 T cells from the total splenocytes.</div>
<ol start="22">
<li>Count the cells using a hemocytometer and bring to a concentration of 1 × 10<sup>6</sup> cells per mL in complete RMPI medium.</li>
<li>Activate the cells with Dynabeads™ Mouse T-Activator CD3/CD28.</li>
</ol>
<p>First, wash the Dynabeads™ in preparation for use, as follows; Transfer the required volume of Dynabeads™ to a 1.5 mL Eppendorf tube and add an equal volume of washing buffer [PBS supplemented with 0.1% (w/v) BSA and 2 mM EDTA, pH 7.4], or at least 1 mL, and pipette five times. Place the Eppendorf on the DynaMag™ Magnet for 1 min and remove the supernatant. Remove the Eppendorf from the DynaMag™ Magnet and suspend the Dynabeads™ in the same volume of culture medium as the initial volume of Dynabeads™ taken. Add 25 μL of Dynabeads™ per 1 × 10<sup>6</sup> CD4 T cells.</p>
<ol start="24">
<li>Seed 1 × 10<sup>6</sup> cells per well in a 24 well plate and incubate at 37°C in a humidified 5% CO<sub>2</sub>-containing incubator for 16–18 h.</li>
</ol>
<h3 id="sec3.3">Retroviral transduction of CD4 T cells</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 8 h</div>
<p>CD4 T cells were retrovirally transduced with the viral supernatant</p>
<p>Day 4: Transduction of CD4 T cells</p>
<ol start="25">
<li>Coat non-treated 24-well plates with 350 μL per well of PBS containing 20 μg/mL RetroNectin®.</li>
</ol>
<div class="pause-point">
<span class="pause-point-title">Pause point:</span> The RetroNectin® coated plates can be stored at 4°C for up to 1 week.</div>
<ol start="26">
<li>Incubate plates for 2 h at 37°C in a humidified 5% CO<sub>2</sub>-containing incubator.</li>
<li>During the incubation, harvest the viral supernatant from the transfected Plat-E cells and centrifuge at <i>800</i> × <i>g</i> for 10 min. Filtrate through a 0.45 μm filter.</li>
</ol>
<div class="pause-point">
<span class="pause-point-title">Pause point:</span> The viral supernatant can be stored at 4°C for up to 3 days.</div>
<ol start="28">
<li>Replace with 500 μL per well of PBS supplemented with 2% (w/v) BSA. Incubate at 20°C–22°C for 30 min. Wash twice with PBS.</li>
</ol>
<div class="caution">
<span class="caution-title">Caution:</span> Ensure BSA is properly washed from the plate by first removing all of the BSA from each well and then washing the wells twice with 1 mL of PBS. Finally ensure all liquid is removed from the wells.</div>
<ol start="29">
<li>Remove the PBS from the washed plates and add 1 mL of the viral supernatant per well.</li>
<li>Wrap the plates with plastic wrap and centrifuge at <i>2000</i> × <i>g</i> for 4 h at 32°C.</li>
<li>Two hours prior to the end of centrifugation, add 80 international units (IU)/mL of recombinant IL-2 to the CD4 T cells.</li>
<li>After 2 h, collect the cells to 15 mL conical tubes and centrifuge at <i>500</i> × <i>g for</i> 5 min. Collect the supernatant and store at 22°C, for not more than 1 h, for use in step 34.</li>
<li>Remove the Dynabeads™ using a DynaMag™ Magnet.</li>
<li>Suspend the cells in the collected supernatant.</li>
<li>Remove the viral supernatant from the plate and add 1 mL of the CD4 T cell suspension per well, i.e., 1 × 10<sup>6</sup> cells per well.</li>
<li>Re-wrap the plate in the plastic wrap and centrifuge at <i>800</i> × <i>g</i> for 30 min at 32°C.</li>
<li>Remove the plastic wrap and store at 37°C in a humidified 5% CO2-containing incubator.</li>
</ol>
<h3 id="sec3.4">Culture and expansion of transduced CD4 T cells</h3>
<div class="timing">
<span class="timing-title">Timing:</span> 10–14 days</div>
<p>The transduced CD4 T cells were expanded in culture in complete RPMI medium supplemented with 20 IU of IL-2 and 10 ng/mL IL-7.</p>
<p>Day 6: Treatment of transduced cells</p>
<ol start="38">
<li>After 48 h, remove 500 μL from each well and add 500 μL complete RPMI medium supplemented with 20 IU of IL-2 and 10 ng/mL IL-7.</li>
</ol>
<p>Day 7: Cell sorting of transduced cells</p>
<ol start="39">
<li>72 h post transduction, collect the cells and sort for the positive population using the 70 μm nozzle of the FACSAria<sup>TM</sup> III Cell Sorter (<a href="#fig2">Figure 2</a>).
<figure id="fig2"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/906-Fig2.jpg" alt="Fig2.jpg">
<figcaption>
<div class="figcaption-title">Figure 2. Representative flow cytometry plots outlining the sorting of the transduced GFP-positive CD4 T cells</div>
<p>Plots (left to right) show the percentage of lymphocytes, gating on single cells and the mean fluorescent intensity (MFI) of GFP-positive cells</p>
</figcaption>
</figure>
</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> Use medium for cell sorting.</div>
<div class="note">
<span class="note-title">Note:</span> The timing of cell sorting can vary but should take place more than 5 days post transduction. It is important to check the fluorescence of the cells before cell sorting.</div>
<ol start="40">
<li>Seed sorted cells, 1 × 10<sup>6</sup> cells per well, in a 24-well plate in complete RPMI medium supplemented with 20 IU of IL-2 and 10 ng/mL IL-7.</li>
</ol>
<p>Day 9: Activation of sorted cells</p>
<ol start="41">
<li>48 h post cell sorting, activate the cells with Dynabeads™ Mouse T-Activator CD3/CD28 in complete RPMI medium, as described in step 23.</li>
</ol>
<p>Day 11: Treatment of cells</p>
<ol start="42">
<li>48 h post cell activation, remove 500 μL of the medium and replace with 500 μL of complete RPMI supplemented with 20 IU of IL-2 and 10 ng/mL IL-7.</li>
</ol>
<div class="note">
<span class="note-title">Note:</span> In order to optimize the protocol and enhance the proliferation and survival of the transduced cells, 10 ng/mL IL-7 was added to the standard RPMI medium supplemented with 20 IU of IL-2 (<a href="#fig3">Figure 3</a>).</div>
<ol start="43">
<li>Every 2 days, while cells are proliferating, carefully pipette and split one well to two. Add 500 μL of fresh complete RPMI supplemented with 20 IU of IL-2 and 10 ng/mL IL-7.</li>
<li>Once the cells are resting, replace half of the medium with fresh medium every second day.</li>
<li>Activate cells with Dynabeads™ every 7–10 days, as required.</li>
</ol>
<figure id="fig3"><img src="https://prod-shared-star-protocols.s3.amazonaws.com/protocols/906-Fig3.jpg" alt="Fig3.jpg">
<figcaption>
<div class="figcaption-title">Figure 3. Proliferation of retroviral-transduced CD4 T cells in the presence of IL2-/IL-7 medium</div>
<p>CD4 GFP T cells were seeded in a 24 well plate (0.5 × 10<sup>6</sup> cells per well) in RPMI medium supplemented with either 20 IU IL-2 and 10 ng/mL IL-7 or the control 20 IU RPMI. Cells were counted every two days post activation with Dynabeads™. Each condition had four wells per experiment and the experiment was repeated three times. Error bars represent mean ± SEM.</p>
</figcaption>
</figure>
</section>
<section>
<h2 id="expected-outcomes">Expected outcomes</h2>
<p>Activation of murine CD4 T cells was performed by co-culturing CD3/CD28 Dynabeads™ with the CD4 T cells for 16–18 h prior to transduction. Coating plates for viral integration with RetroNectin® significantly increased the yield of transduced CD4 T cells. We also observed an increased yield of transduced CD4 T cells by incubating the cells with 80 IU of recombinant IL-2 two hours prior to viral transduction. Evaluation of GFP expression by flow cytometry demonstrated an exclusive gene transfer into murine CD4 T cells. Supplementing the transduced murine CD4 T cells with IL-2 and IL-7 increased their viability and proliferation capacity (<a href="#fig3">Figure 3</a>).</p>
</section>
<section>
<h2 id="limitations">Limitations</h2>
<p>Since the majority of lentiviruses poorly transduce murine T cells, RV are the favored choice for gene delivery into murine T cells (<a href="#bib8">Kerkar et al., 2011</a>). One of the main restrictions of RV is the transduction of proliferating cells, unlike lentiviruses that can transduce also non-proliferating cells (<a href="#bib4">Cepko and Pear, 2001</a>). Since it is essential to transduce the CD4 T cells during proliferation, we activate the cells with Dynabeads™ Mouse T-Activator CD3/CD28 16–18 h prior to transduction and supplement with 80 IU of recombinant IL-2 for 2 h prior the transduction. It is thus important to validate cell proliferation prior to transduction.</p>
<p>The vector size can influence the transduction efficiency, with both retroviral and lentiviral vectors having limited cargo capacity (<a href="#bib12">Simmons and Alberola-Ila, 2016</a>). The limit of the DNA fragment size for retroviral gene transfer is around 11 kb, with DNA fragments larger than 8 kb presenting difficulties to work with (Current protocols in molecular biology; <a href="#bib12">Simmons and Alberola-Ila, 2016</a>). The titer of virus produced is in inversely proportional to construct size (<a href="#bib9">Kumar et al., 2001</a>).</p>
</section>
<section>
<h2 id="troubleshooting">Troubleshooting</h2>
<h3 id="sec6.1">Problem 1</h3>
<p>Viability of the donor spleens. (step 15)</p>
<h3 id="sec6.2">Potential solution</h3>
<p>We recommend using an overdose of isoflurane to sacrifice the donor mice. An alternative euthanasia is CO<sub>2</sub> overdose, but this can cause necrosis of the spleen and therefore affect the quantity and viability of the splenocytes.</p>
<h3 id="sec6.3">Problem 2</h3>
<p>Low RV transduction efficiency. (steps 2, 8, 14, 25, and 30)</p>
<h3 id="sec6.4">Potential solution</h3>
<p>Coat tissue culture plates with poly-D-lysine before seeding Plat-E cells to enhance adherence. Otherwise, they are loosely attached and easily dislodged.</p>
<p>Check the concentration of the plasmid prior to transfection.</p>
<p>Check fluorescence of the Plat-E cells post transfection.</p>
<p>Use non–coated plates for spin transduction to increase transduction efficiency.</p>
<p>Use RetroNectin to facilitate adsorption of RV to target cells.</p>
<p>Keep cells above 22°C to maintain activity. Set centrifuge to 32°C for spin-transduction.</p>
<h3 id="sec6.5">Problem 3</h3>
<p>Insufficient activation of CD4 T cells. (steps 24 and 31)</p>
<h3 id="sec6.6">Potential solution</h3>
<p>Transduce cells 16–18 h post activation with Dynabeads<sup>TM</sup>.</p>
<p>Add IL-2 two hours prior to transduction. IL-2 should be aliquoted and frozen in appropriate volumes as freeze/thaw cycles can reduce the efficacy of IL-2.</p>
<p>For activation, seed cells at a density of 1 × 10<sup>6</sup> cells per well in a 24-well plate.</p>
<h3 id="sec6.7">Problem 4</h3>
<p>Viability of the CD4 T cells post transduction. (steps 28 and 36)</p>
<h3 id="sec6.8">Potential solution</h3>
<p>Carefully wash plates after blocking with BSA by first removing all the BSA and then by washing the well twice with 1 mL of PBS. Finally remove all of the liquid.</p>
<p>Do not exceed the recommend centrifugation time of CD4 T cells to viral-coated plates. We recommend 30 min.</p>
<h3 id="sec6.9">Problem 5</h3>
<p>Poor viability of the CD4 T cells after cell sorting. (steps 39 and 41)</p>
<h3 id="sec6.10">Potential solution</h3>
<p>Perform cell sorting in cell sorting medium.</p>
<p>Allow sorted cells to rest for at least 48 h before the following activation.</p>
<h3 id="sec6.11">Problem 6</h3>
<p>Limited fluorescence of CD4 T cells.</p>
<h3 id="sec6.12">Potential solution</h3>
<p>Transduce the CD4 T cells twice to increase the transduction efficiency.</p>
</section>
<section>
<h2 id="references">References</h2>
<p id="bib1">Alizadeh, D., Wong, R.A., Yang, X., Wang, D., Pecoraro, J., Kuo, C., Aguilar, B., Qi, Y., Ann, D.K., Starr, R., et al. (2019). IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. <i>7</i>, 759-772. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref1">View at publisher</a></p>
<p id="bib2">Alvarez-Fernández, C., Escribà-Garcia, L., Vidal, S., Sierra, J., and Briones, J. (2016). A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy. J. Transl. Med. <i>14</i>, 4-13. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref2">View at publisher</a></p>
<p id="bib3">Coffin, J.M., Hughes, S.H., and Varmus, H.E. (1997). Retroviruses (Cold Spring Harbor Laboratory Press). <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref3">View at publisher</a></p>
<p id="bib4">Cepko, C. and Pear, W. (2001). Overview of the retrovirus transduction system. Curr. Protoc. Mol. Biol. <i>Chapter 9</i>. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref4">View at publisher</a></p>
<p id="bib5">Engels, B., Cam, H., Schüler, T., Indraccolo, S., Gladow, M., Baum, C., Blankenstein, T., and Uckert, W. (2003). Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. <i>14</i>, 1155-1168. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref5">View at publisher</a></p>
<p id="bib6">Eremenko, E., Mittal, K., Berner, O., Kamenetsky, N., Nemirovsky, A., Elyahu, Y., and Monsonego, A. (2019). BDNF-producing, amyloid β-specific CD4 T cells as targeted drug-delivery vehicles in Alzheimer’s disease. EBioMedicine <i>43</i>, 424-434. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref6">View at publisher</a></p>
<p id="bib7">Hurton, L.V., Singh, H., Najjar, A.M., Switzer, K.C., Mi, T., Maiti, S., Olivares, S., Rabinovich, B., Huls, H., Forget, M., et al. (2016). Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl. Acad. Sci. U S A <i>113</i>, E7788-E7797. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref7">View at publisher</a></p>
<p id="bib8">Kerkar, S.P., Sanchez-Perez, L., Yang, S., Borman, Z.A., Muranski, P., Ji, Y., Chinnasamy, D., Kaiser, A.D.M., Hinrichs, C.S., Klebanoff, C.A., et al. (2011). Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J. Immunother. <i>34</i>, 343-352. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref8">View at publisher</a></p>
<p id="bib9">Kumar, M., Keller, B., Makalou, N., and Sutton, R.E. (2001). Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. <i>12</i>, 1893-1905. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref9">View at publisher</a></p>
<p id="bib10">Morita, S., Kojima, T., and Kitamura, T. (2000). Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther <i>7</i>, 1063-1066. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref10">View at publisher</a></p>
<p id="bib11">Rathmell, J.C., Farkash, E.A., Gao, W., and Thompson, C.B. (2001). IL-7 Enhances the Survival and Maintains the Size of Naive T Cells. J. Immunol. <i>167</i>, 6869-6876. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref11">View at publisher</a></p>
<p id="bib12">Simmons, A. and Alberola-Ila, J. (2016). Retroviral Transduction of T Cells and T Cell Precursors. Methods Mol. Biol. 99-108. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref12">View at publisher</a></p>
<p id="bib13">Xu, Y., Zhang, M., Ramos, C.A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C.J., Gee, A.P., Heslop, H.E., et al. (2014). Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood <i>123</i>, 3750-3759. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref13">View at publisher</a></p>
<p id="bib14">Zhang, H., Zhao, P., and Huang, H. (2020). Engineering better chimeric antigen receptor T cells. Exp. Hematol. Oncol. <i>9</i>, 1-13. <a class="external-link" href="http://refhub.elsevier.com/S2666-1667(21)00426-3/sref14">View at publisher</a></p>
</section>
<section>
<h2 id="article-info">Article info</h2>
<h3>Resource availability</h3>
<h4>Lead contact</h4>
<p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ekaterina Eremenko (<a href="mailto:eremenkoem@gmail.com">eremenkoem@gmail.com</a>).</p>
<h4>Materials availability</h4>
<p>This study did not generate new unique reagents.</p>
<h4>Data and code availability</h4>
<p>This protocol did not generate/need datasets.</p>
<h3>Acknowledgments</h3>
<p>This research was supported by funding from the National Institute for Biotechnology in the Negev Ltd. and the Ministry of Science and Technology (grant # 3-16148). The graphical abstract and <a href="#fig1">Figure 1</a> were created with <a href="http://BioRender.com">BioRender.com</a>.</p>
<h3>Author contributions</h3>
<p>E.E. and Z.V.T. performed the experiments. E.E., Z.V.T., A.P., and A.M. wrote the manuscript. All authors read, revised, and approved the manuscript.</p>
<h3>Declaration of interests</h3>
<p>The authors declare no competing interests.</p>
</section>
</article>